ArticleCancer gene therapy2007
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.
Article in Cancer gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.Oncoimmunology · 2025Article
- Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy.Molecular cancer · 2025Review
- Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.Journal for immunotherapy of cancer · 2022Article
- Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.Cancer immunology research · 2022Article
- Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.Oncoimmunology · 2022Article
- Engineered mRNA and the Rise of Next-Generation Antibodies.Antibodies (Basel, Switzerland) · 2021Review
- Overcoming the challenges associated with CD3+ T-cell redirection in cancer.British journal of cancer · 2021Review
- Review
- Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.Journal for immunotherapy of cancer · 2020Article
- Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.Cellular & molecular immunology · 2020Review
- Engineering Immune Cells forFrontiers in immunology · 2020Review
- Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.Molecular therapy oncolytics · 2019Review
- Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.Cancer immunology, immunotherapy : CII · 2018Article
- T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.Molecular therapy oncolytics · 2017Article
- Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.Gene therapy · 2017Article
- CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains.Scientific reports · 2016Article
- T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies.Scientific reports · 2016Article
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.Blood cancer journal · 2016Article
- Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.Oncoimmunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Infiltrating T lymphocytes are found in many malignancies, but they appear to be mostly anergic and do not attack the tumor, presumably because of defective T-cell activation events. Recently, we described a strategy for the tumor-specific polyclonal activation of tumor-resident T lymphocytes based on the in situ production of recombinant bispecific antibodies (bsAbs) by transfected nonhematological cell lines. Here, we have constructed a novel HIV-1-based lentiviral vector for efficient gene transduction into various human hematopoietic cell types. Several myelomonocytic and lymphocytic cell lines secreted the anti-carcinoembryonic antigen (CEA) x anti-CD3 diabody in a functionally active form with CD3(+) T-cell lines being the most efficient secretors. Furthermore, primary human peripheral blood lymphocytes (PBLs) were also efficiently transduced and secreted high levels of functional diabody. Importantly gene-modified PBLs significantly reduced in vivo tumor growth rates in xenograft studies. These results demonstrate, for the first time, the utility of lentiviral vectors for sustained expression of recombinant bsAbs in human T lymphocytes. Such T lymphocytes, transduced ex vivo to secrete the activating diabody in autocrine fashion, may provide a promising route for a gene therapy strategy for solid human tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.